Biomarkers of drug resistance in ovarian cancer – an update

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11–27.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.
   PubMed Web of Science ®Google Scholar
• Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789.
   PubMed Web of Science ®Google Scholar
• Bashashati A, Ha G, Tone A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231(1):21–34.
   PubMed Web of Science ®Google Scholar
• Davidson B. Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn. 2016;16(5):569–578.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Carcangiu ML, Herrington CS et al. eds. WHO classification of tumours of female reproductive organs. Lyon: IARC; 2014.
   Google Scholar
• Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res. 2017;23(7):1862–1874.
   PubMed Web of Science ®Google Scholar
• Ayhan A, Kuhn E, Wu RC, et al. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Mod Pathol. 2017;30(2):297–303.
   PubMed Web of Science ®Google Scholar
• Huang KC, Yang J, Ng MC, et al. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. Eur J Cancer. 2016;67:152–163.
   PubMed Web of Science ®Google Scholar
• Nguyen TM, Shin IW, Lee TJ, et al. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer. Gynecol Oncol. 2016;140(3):545–553.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Zhu H, Lee JH, et al. BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Res. 2016;76(21):6320–6330.
   PubMed Web of Science ®Google Scholar
• Raghavan S, Mehta P, Ward MR, et al. Personalized medicine-based approach to model patterns of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids. Clin Cancer Res. 2017;23(22):6934–6945.
   PubMed Web of Science ®Google Scholar
• Ffrench B, Gasch C, Hokamp K, et al. CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy. Cell Death Dis. 2017;8(10):e3128.
   PubMedGoogle Scholar
• Jung JG, Shih IM, Park JT, et al. Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Res. 2016;76(21):6351–6361.
   PubMed Web of Science ®Google Scholar
• Ramadoss S, Sen S, Ramachandran I, et al. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene. 2017;36(11):1537–1545.
   PubMed Web of Science ®Google Scholar
• Coffman LG, Pearson AT, Frisbie LG, et al. Ovarian carcinoma-associated mesenchymal stem cells arise from tissue-specific normal stroma. Stem Cells.2018 Oct 23. Epub ahead of print. DOI:10.1002/stem.2932.
   PubMed Web of Science ®Google Scholar
• Au KK, Le Page C, Ren R, et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J Pathol Clin Res. 2016;2(4):259–270.
   PubMedGoogle Scholar
• Wang W, Kryczek I, Dostál L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165(5):1092–1105.
   PubMed Web of Science ®Google Scholar
• Cortés M, Sanchez-Moral L, de Barrios O, et al. Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. EMBO J. 2017;36(22):3336–3355.
   PubMed Web of Science ®Google Scholar
• Özeş AR, Miller DF, Özeş ON, et al. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016;35(41):5350–5361.
   PubMed Web of Science ®Google Scholar
• Previs RA, Armaiz-Pena GN, Ivan C, et al. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017;109(7):djw296.
   Google Scholar
• Avril S, Dincer Y, Malinowsky K, et al. Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. Oncotarget. 2017;8(58):97851–97861.
   PubMedGoogle Scholar
• Byeon Y, Lee JW, Choi WS, et al. CD44-Targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 2018;78(21):6247–6256.
   PubMed Web of Science ®Google Scholar
• Dorayappan KDP, Wanner R, Wallbillich JJ, et al. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene. 2018;37(28):3806–3821.
   PubMed Web of Science ®Google Scholar
• Zhou C, Clamp A, Backen A, et al. Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. Br J Cancer. 2016;115(2):228–235.
   PubMed Web of Science ®Google Scholar
• Pasquier J, Vidal F, Hoarau-Véchot J, et al. Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8. J Transl Med. 2018;16(1):271.
   PubMedGoogle Scholar
• Dalton HJ, Pradeep S, McGuire M, et al. Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression. Clin Cancer Res. 2017;23(22):7034–7046.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition. J Clin Oncol. 2017;35(11):1240–1249.
   PubMed Web of Science ®Google Scholar
• Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018;9(1):3970.
   PubMedGoogle Scholar
• Kondrashova O, Nguyen M, Shield-Artin K, et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2017;7(9):984–998.
   PubMed Web of Science ®Google Scholar
• Couturier AM, Fleury H, Patenaude AM, et al. Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction. Nucleic Acids Res. 2016;44(22):10879–10897.
   PubMed Web of Science ®Google Scholar
• Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–1280.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Comino-Méndez I, de Bruijn I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017;23(21):6708–6720.
   PubMed Web of Science ®Google Scholar
• Lambrechts S, Smeets D, Moisse M, et al. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. Eur J Cancer. 2016;53:51–64.
   PubMed Web of Science ®Google Scholar
• Dwivedi SK, Mustafi SB, Mangala LS, et al. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016;7(12):15093–15104.
   PubMed Web of Science ®Google Scholar
• Kanlikilicer P, Bayraktar R, Denizli M, et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100–112.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Aguayo C, Monroig PDC, Redis RS, et al. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017;3:17029.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, McGuire M, Wu SY, et al. PRKRA/PACT expression promotes chemoresistance of mucinous ovarian cancer. Mol Cancer Ther. 2019;18(1):162–172.
   PubMed Web of Science ®Google Scholar
• Liu J, Agopiantz M, Poupon J, et al. Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer. Clin Cancer Res. 2017;23(21):6516–6528.
   PubMed Web of Science ®Google Scholar
• Chen Y, Camacho SC, Silvers TR, et al. Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin Cancer Res. 2017;23(6):1552–1563.
   PubMed Web of Science ®Google Scholar
• DeVorkin L, Hattersley M, Kim P, et al. Autophagy inhibition enhances sunitinib efficacy in clear cell ovarian carcinoma. Mol Cancer Res. 2017;15(3):250–258.
   PubMed Web of Science ®Google Scholar
• Cornelison R, Dobbin ZC, Katre AA, et al. Targeting RNA-polymerase I in both chemosensitive and chemoresistant populations in epithelial ovarian cancer. Clin Cancer Res. 2017;23(21):6529–6540.
   PubMed Web of Science ®Google Scholar
• de Leon M, Cardenas H, Vieth E, et al. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol. 2016;142(3):539–547.
   PubMed Web of Science ®Google Scholar
• Kritsch D, Hoffmann F, Steinbach D, et al. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Int J Cancer. 2017;141(8):1600–1614.
   PubMed Web of Science ®Google Scholar
• Coscia F, Lengyel E, Duraiswamy J, et al. Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer. Cell. 2018;175(1):159–170.e16.
   PubMed Web of Science ®Google Scholar
• Yang SYC, Lheureux S, Karakasis K, et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med. 2018;10(1):81.
   PubMedGoogle Scholar
• Anastasi E, Gigli S, Santulli M, et al. Role of galectin-3 combined with multi- detector contrast enhanced computed tomography in predicting disease recurrence in patients with ovarian cancer. Asian Pac J Cancer Prev. 2017;18(5):1277–1282.
   PubMedGoogle Scholar
• Liu JF, Palakurthi S, Zeng Q, et al. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res. 2017;23(5):1263–1273.
   PubMed Web of Science ®Google Scholar
• Tomar T, de Jong S, Alkema NG, et al. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med. 2016;8(1):107.
   PubMedGoogle Scholar
• Zervantonakis IK, Iavarone C, Chen HY, et al. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017;8(1):365.
   PubMedGoogle Scholar
• Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8(11):1404–1421.
   PubMed Web of Science ®Google Scholar